Marshall Wace
FSTX

Marshall Wace’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Marshall Wace’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,456
Closed -$37K – 4019
2022
Q1 		$37K Buy
+10,456
New +$38.6K ﹤0.01% 3255

Other funds holding FSTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace's FSTX Position: Q2 2022 in Review

Marshall Wace sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2022, closing a stake of 10,456 shares — an estimated $37K sold.

Marshall Wace first reported a position in FSTX in Q1 2022 and held it in 1 quarter. The position peaked at $37K in Q1 2022. 53 funds tracked by Wall St. Rank hold FSTX as of Q2 2022.

  • Marshall Wace reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Marshall Wace sold 10,456 F-star Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $37K.
  • Marshall Wace first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Marshall Wace's F-star Therapeutics, Inc. Common Stock position peaked at $37K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.